A Simultaneous Inhibition of ID1 and ID3 Protects Against Pulmonary Fibrosis

Area of Science:

• Pulmonary Medicine
• Molecular Biology
• Fibrosis Research

Background:

• Idiopathic pulmonary fibrosis (IPF) is a fatal lung disease with limited treatment options.
• The role of Inhibitor of DNA binding (ID) proteins, regulated by Transforming Growth Factor-b, in IPF pathogenesis is not well understood.
• This study investigates ID protein expression and function in IPF.

Purpose of the Study:

• To assess the expression of ID proteins in IPF lungs and lung fibroblasts.
• To determine the therapeutic potential of inhibiting ID proteins in IPF.
• To elucidate the mechanisms by which ID proteins influence fibroblast behavior in pulmonary fibrosis.

Main Methods:

• Evaluated ID protein expression in human and mouse fibrotic lung tissues and fibroblasts.
• Utilized genetic (knockdown, knockout) and pharmacological approaches to inhibit ID1/ID3.
• Assessed the effects of ID1/ID3 modulation on human lung fibroblast proliferation and differentiation in vitro and pulmonary fibrosis in vivo.

Main Results:

• ID1 and ID3 protein levels were elevated in fibrotic lung fibroblasts.
• Inhibition of ID1/ID3 reduced fibroblast proliferation and differentiation into myofibroblasts.
• Genetic and pharmacological inhibition of ID1/ID3 attenuated pulmonary fibrosis in vivo, improving lung function and reducing fibrotic burden.

Conclusions:

• Simultaneous inhibition of ID1 and ID3 effectively attenuates pulmonary fibrosis.
• Targeting ID1/ID3 presents a novel therapeutic strategy for IPF.
• ID1/ID3 inhibition impacts fibroblast proliferation via cell cycle genes and differentiation via the MEK/ERK pathway.